JP2015509536A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509536A5
JP2015509536A5 JP2014561029A JP2014561029A JP2015509536A5 JP 2015509536 A5 JP2015509536 A5 JP 2015509536A5 JP 2014561029 A JP2014561029 A JP 2014561029A JP 2014561029 A JP2014561029 A JP 2014561029A JP 2015509536 A5 JP2015509536 A5 JP 2015509536A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
methyl
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014561029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029084 external-priority patent/WO2013134243A1/en
Publication of JP2015509536A publication Critical patent/JP2015509536A/ja
Publication of JP2015509536A5 publication Critical patent/JP2015509536A5/ja
Ceased legal-status Critical Current

Links

JP2014561029A 2012-03-07 2013-03-05 Rafキナーゼ阻害剤として有用な2−アミノ,6−フェニル置換ピリド[2,3−d]ピリミジン誘導体 Ceased JP2015509536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07
US61/607,702 2012-03-07
PCT/US2013/029084 WO2013134243A1 (en) 2012-03-07 2013-03-05 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2015509536A JP2015509536A (ja) 2015-03-30
JP2015509536A5 true JP2015509536A5 (OSRAM) 2016-04-21

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561029A Ceased JP2015509536A (ja) 2012-03-07 2013-03-05 Rafキナーゼ阻害剤として有用な2−アミノ,6−フェニル置換ピリド[2,3−d]ピリミジン誘導体

Country Status (39)

Country Link
US (2) US9334267B2 (OSRAM)
EP (1) EP2850082B1 (OSRAM)
JP (1) JP2015509536A (OSRAM)
KR (1) KR20140129087A (OSRAM)
CN (1) CN104302646B (OSRAM)
AP (1) AP2014007899A0 (OSRAM)
AR (1) AR090151A1 (OSRAM)
AU (1) AU2013230146B2 (OSRAM)
BR (1) BR112014018528A8 (OSRAM)
CA (1) CA2863673A1 (OSRAM)
CL (1) CL2014002220A1 (OSRAM)
CO (1) CO7010837A2 (OSRAM)
CR (1) CR20140378A (OSRAM)
CY (1) CY1117846T1 (OSRAM)
DK (1) DK2850082T3 (OSRAM)
DO (1) DOP2014000200A (OSRAM)
EA (1) EA024824B1 (OSRAM)
EC (1) ECSP14017584A (OSRAM)
ES (1) ES2584387T3 (OSRAM)
HK (1) HK1202541A1 (OSRAM)
HR (1) HRP20160654T1 (OSRAM)
HU (1) HUE028095T2 (OSRAM)
IL (1) IL234052A (OSRAM)
IN (1) IN2014MN01575A (OSRAM)
LT (1) LT2850082T (OSRAM)
MA (1) MA37316B1 (OSRAM)
ME (1) ME02423B (OSRAM)
MX (1) MX2014010701A (OSRAM)
NZ (1) NZ627454A (OSRAM)
PE (1) PE20142338A1 (OSRAM)
PH (1) PH12014501986B1 (OSRAM)
PT (1) PT2850082T (OSRAM)
RS (1) RS54840B1 (OSRAM)
SG (1) SG11201404969YA (OSRAM)
SI (1) SI2850082T1 (OSRAM)
TN (1) TN2014000375A1 (OSRAM)
TW (1) TW201348233A (OSRAM)
UA (1) UA112340C2 (OSRAM)
WO (2) WO2013134243A1 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
MX2018015353A (es) * 2016-06-10 2019-09-09 Novartis Ag Usos terapeuticos de un inhibidor de c-raf.
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CN110545853A (zh) * 2017-04-28 2019-12-06 石英治疗有限公司 Raf降解偶联化合物
PE20210163A1 (es) 2017-12-21 2021-01-26 Boehringer Ingelheim Int Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SMT202500389T1 (it) 2018-12-28 2025-11-10 Deciphera Pharmaceuticals Llc Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
LT3921030T (lt) 2019-02-06 2024-01-25 Eli Lilly And Company 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai
AR118119A1 (es) * 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
AU2020268814A1 (en) 2019-05-03 2021-12-16 Kinnate Biopharma Inc. Inhibitors of RAF kinases
PE20220592A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
AU2021285032A1 (en) 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN116507627A (zh) 2020-11-02 2023-07-28 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ,エルエルシー Gcn2およびperkキナーゼ阻害剤およびその使用方法
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Sos1阻害剤およびその使用
IL307908A (en) 2021-04-23 2023-12-01 Kinnate Biopharma Inc Cancer treatment with a RAF inhibitor
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
IL312905A (en) 2021-12-01 2024-07-01 Boehringer Ingelheim Int Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250313553A1 (en) 2021-12-01 2025-10-09 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20240133793A (ko) 2021-12-09 2024-09-04 데시페라 파마슈티칼스, 엘엘씨. Raf 키나아제 억제제 및 그 사용 방법
US20230357179A1 (en) 2021-12-09 2023-11-09 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
US20250382288A1 (en) 2021-12-23 2025-12-18 Boehringer Ingelheim International Gmbh 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CA3266173A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING
AR130848A1 (es) 2022-10-26 2025-01-22 Boehringer Ingelheim Int Compuestos heterocíclicos con capacidad para activar el receptor sting
KR20250092268A (ko) 2022-10-26 2025-06-23 베링거 인겔하임 인터내셔날 게엠베하 Sting을 활성화시킬 수 있는 헤테로사이클릭 화합물
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
US20250205161A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US20250313560A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033472A1 (en) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
AR080151A1 (es) * 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Similar Documents

Publication Publication Date Title
JP2015509536A5 (OSRAM)
HRP20160654T1 (hr) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
JP2014502638A5 (OSRAM)
JP2016522266A5 (OSRAM)
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
IL292161B1 (en) New methylquinazolinone derivatives
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
JP2014527042A5 (OSRAM)
JP2017519027A5 (OSRAM)
JP2016523270A5 (OSRAM)
JP2018531274A5 (ja) 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗SIRPa化合物
JP2020510668A5 (OSRAM)
JP2014534269A5 (OSRAM)
GEP201706692B (en) Biaryl amide compounds as kinase inhibitors
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
JP2012512158A5 (OSRAM)
JP2013510120A5 (OSRAM)
JP2019510768A5 (OSRAM)
HRP20120918T1 (hr) Aminopirazolski spoj
MX381000B (es) Cristales de compuesto azabicíclico.
JP2016537382A5 (OSRAM)
JP2017517538A5 (OSRAM)
JP2015516427A5 (OSRAM)